|
Real-time Estimate
Cboe BZX
22:33:22 12/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 8.375 USD | -2.05% |
|
+3.15% | +7.12% |
| 10-05 | Biocryst Pharmaceuticals, Inc. Announces Formation of Scientific Advisory Board | CI |
| 10-05 | BioCryst Pharmaceuticals Forms Scientific Advisory Board as R&D Model Evolves | MT |
| Market Cap | 2.18B 1.96B 1.82B 1.65B 3.12B 209B 3.14B 21.91B 8.58B 108B 8.21B 8.03B 347B | P/E 2026 * |
-3.7x | P/E 2027 * | 12.9x |
|---|---|---|---|---|---|
| Enterprise Value | 2.3B 2.06B 1.92B 1.74B 3.29B 220B 3.31B 23.09B 9.04B 114B 8.65B 8.46B 366B | EV / Sales 2026 * |
3.24x | EV / Sales 2027 * | 2.81x |
| Free-Float |
94.69% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| BCRX | Delayed | |
CBOE
| BCRX | Real-time | |
|
Tradegate
| BO1 | Real-time | |
|
Mexican S.E.
| BCRX * | End-of-day quote | |
|
Boerse Muenchen
| BO1 | Real-time | |
|
Deutsche Boerse AG
| BO1 | Delayed | |
|
Börse Stuttgart
| BO1 | Delayed | |
|
Berne S.E.
| BO1 | End-of-day quote |
Last Transcript: BioCryst Pharmaceuticals, Inc.
| 1 day | -2.05% | ||
| 1 week | +3.15% | ||
| Current month | +0.30% | ||
| 1 month | +1.52% | ||
| 3 months | -15.69% | ||
| 6 months | -11.21% | ||
| Current year | +7.12% |
| 1 week | 7.86 |  | 8.6 |
| 1 month | 7.86 | | 9.04 |
| Current year | 6.23 | | 11.22 |
| 1 year | 6 | | 11.22 |
| 3 years | 4.03 | | 11.31 |
| 5 years | 4.03 | | 19.99 |
| 10 years | 1.38 | | 19.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
Charles Gayer
CEO | Chief Executive Officer | 55 | 01/01/2026 |
Babar Ghias
DFI | Director of Finance/CFO | 47 | 07/07/2025 |
Sandeep Menon
CTO | Chief Tech/Sci/R&D Officer | 51 | 06/04/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Stonehouse
BRD | Director/Board Member | 65 | 01/01/2007 |
Theresa Heggie
BRD | Director/Board Member | 64 | 03/12/2018 |
Charles Gayer
BRD | Director/Board Member | 55 | 01/01/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/08/26 | Free | Director | 644 | 0.0003% | ||
| 31/08/26 | Free | Director | 644 | 0.0003% | ||
| 31/08/26 | Free | Director | 1,288 | 0.0005% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.05% | +3.15% | +18.68% | +39.72% | 2.18B | |
| -2.59% | -5.70% | +50.69% | +79.01% | 70.61B | |
| +0.66% | -9.75% | +5.10% | +52.62% | 51.01B | |
| +0.31% | -0.14% | +8.42% | +32.99% | 48.1B | |
| +1.26% | -1.48% | +28.66% | +32.67% | 42.78B | |
| +1.85% | -6.92% | +296.51% | +698.76% | 40.67B | |
| -0.94% | -2.88% | +7.40% | +99.30% | 40.3B | |
| -2.13% | -1.64% | +8.63% | +46.15% | 30.59B | |
| -2.23% | -4.96% | +46.01% | +6.04% | 28.16B | |
| -0.47% | -0.96% | -5.47% | -11.20% | 24.36B | |
| Average | -0.61% | -1.93% | +46.46% | +107.61% | 37.88B | |
| Weighted average by Cap. | -0.47% | -2.90% | +50.94% | +118.98% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 710M 636M 593M 537M 1.01B 67.88B 1.02B 7.12B 2.79B 35.03B 2.67B 2.61B 113B | 739M 661M 616M 559M 1.05B 70.61B 1.06B 7.41B 2.9B 36.44B 2.77B 2.71B 117B |
| Net income | -582M -521M -486M -441M -831M -55.66B -836M -5.84B -2.29B -28.72B -2.19B -2.14B -92.42B | 181M 162M 151M 137M 259M 17.33B 260M 1.82B 712M 8.94B 681M 666M 28.78B |
| Net Debt | 118M 106M 98.4M 89.25M 168M 11.27B 169M 1.18B 463M 5.82B 443M 433M 18.72B | -109M -97.13M -90.55M -82.13M -155M -10.37B -156M -1.09B -426M -5.35B -408M -399M -17.22B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/10/26 | $8.355 | -2.28% | 1,586,505 |
| 09/10/26 | $8.550 | +3.14% | 2,307,844 |
| 08/10/26 | $8.290 | -1.31% | 5,121,765 |
| 07/10/26 | $8.400 | +5.66% | 5,122,732 |
| 06/10/26 | $7.950 | -1.85% | 3,944,024 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BCRX Stock
Select your edition
All financial news and data tailored to specific country editions
